HealthKart, the largest omnichannel nutrition platform, has raised $153 million in a funding round led by ChrysCapital and Motilal Oswal Alternates, that have been joined by existing investor A91 Partners and Neo Group. This round once more signifies the growing investor confidence in HealthKart’s business model as well as market potential.
PC: Entrackr
Revenue Milestone and Profitability
HealthKart achieved the milestone of ₹1,000 crore revenue in FY24. Crossing this revenue was one of the important milestones the firm had marked in its growth curve. In the same fiscal year of FY24, the firm also marked the milestone of achieving full-year EBITDA profitability. The official audited numbers for the fiscal are yet to be filed, but the company had reported revenue of ₹832 crore for FY23 with the same fiscal posting a loss at ₹76 crore.
Some of the most known nutrition brands in the company are operating in MuscleBlaze, HKVitals, and Gritzo. The company has a robust online presence and runs over 200 retail stores across 90 cities, thus making it the biggest health and wellness sector company.
Previous Funding and Growth Strategy
Before this round, HealthKart had raised $135 million in December 2022, led by Temasek, with contributions from A91 Partners and Kae Capital. HealthKart has raised about $360 million in funding to date. The funding has helped the company increase products offered to consumers and boost market reach in a rather crowded nutrition landscape.
Employee ESOP Buyback Program
In conjunction with the funding announcement, HealthKart revealed its first-ever employee stock ownership plan (ESOP) buyback, valued at ₹55 crore (approximately $6.5 million). This buyback initiative is designed to benefit both current and former employees, reflecting the company’s commitment to rewarding its workforce and enhancing employee morale.
According to TheKredible, over 20 startups have adopted ESOP buyback, liquidity, and payout programs amounting to about $200 million in the calendar year 2024. This has subsumed an emergent recognition, by most startups of late, of the need for employee engagement and retention strategies.
Historical Background and Success Stories
The company started by concentrating primarily on health supplements and nutritional products. HealthKartPlus, an earlier spin out was the generic drug search business in 2015, which was branded as 1mg and currently trades under Tata 1mg Technologies Private Limited. In this regard, it allowed HealthKart to focus core on nutrition and wellness products that led to its current success.
Market Position and Future Outlook
As the HealthKart business scale up, it faces competition from many other players in the nutrition and wellness space. Yet with its well-established brand presence and comprehensive product offerings and strategic retail partnerships, this places it very well in the market. The funding and ESOP buyback will not only strengthen its financial position but also make it a more attractive employer in the industry.
In conclusion, a successful round of fundraising and the adoption of the ESOP buyback program by HealthKart will be a fair reflection of the company’s solid performance and commitment to its employees. With a solid revenue milestone established, HealthKart now has a clear direction towards continued profitability. HealthKart is so well positioned for continued growth in this dynamic health and wellness market. As the company charts its course through the landscape, the focus on innovation and expansion for competitiveness seems inevitable.
